| Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy MK Shim, J Park, HY Yoon, S Lee, W Um, JH Kim, SW Kang, JW Seo, ... Journal of Controlled Release 294 (28), 376-389, 2019 | 120 | 2019 |
| Necroptosis‐Inducible Polymeric Nanobubbles for Enhanced Cancer Sonoimmunotherapy W Um, H Ko, DG You, S Lim, G Kwak, MK Shim, S Yang, J Lee, Y Song, ... Advanced Materials 32 (16), 1907953, 2020 | 114 | 2020 |
| Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy S Lim, J Park, MK Shim, W Um, HY Yoon, JH Ryu, DK Lim, K Kim Theranostics 9 (25), 7906, 2019 | 103 | 2019 |
| Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy J Choi, MK Shim, S Yang, HS Hwang, H Cho, J Kim, WS Yun, Y Moon, ... ACS nano 15 (7), 12086–12098, 2021 | 99 | 2021 |
| Cathepsin B‐specific metabolic precursor for in vivo tumor‐specific fluorescence imaging MK Shim, HY Yoon, JH Ryu, H Koo, S Lee, JH Park, JH Kim, S Lee, ... Angewandte Chemie 128 (47), 14918-14923, 2016 | 91 | 2016 |
| Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity S Yang, MK Shim, WJ Kim, J Choi, GH Nam, J Kim, J Kim, Y Moon, ... Biomaterials 272, 120791, 2021 | 89 | 2021 |
| Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery MK Shim, S Yang, IC Sun, K Kim Advanced Drug Delivery Reviews, 114177, 2022 | 75 | 2022 |
| Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy MK Shim, Y Moon, S Yang, J Kim, H Cho, S Lim, HY Yoon, JK Seong, ... Biomaterials 261, 120347, 2020 | 73 | 2020 |
| Effects of tumor microenvironments on targeted delivery of glycol chitosan nanoparticles JY Yhee, S Jeon, HY Yoon, MK Shim, H Ko, J Min, JH Na, H Chang, ... Journal of Controlled Release 267, 223-231, 2017 | 68 | 2017 |
| In situ one-step fluorescence labeling strategy of exosomes via bioorthogonal click chemistry for real-time exosome tracking in vitro and in vivo S Song, MK Shim, S Lim, Y Moon, S Yang, J Kim, Y Hong, HY Yoon, ... Bioconjugate Chemistry 31 (5), 1562–1574, 2020 | 64 | 2020 |
| Caspase-3/-7-specific metabolic precursor for bioorthogonal tracking of tumor apoptosis MK Shim, HY Yoon, S Lee, MK Jo, J Park, JH Kim, SY Jeong, IC Kwon, ... Scientific reports 7 (1), 16635, 2017 | 59 | 2017 |
| Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death Y Moon, MK Shim, J Choi, S Yang, J Kim, WS Yun, H Cho, JY Park, Y Kim, ... Theranostics 12 (5), 1999, 2022 | 55 | 2022 |
| Visible light-induced apoptosis activatable nanoparticles of photosensitizer-DEVD-anticancer drug conjugate for targeted cancer therapy W Um, J Park, H Ko, S Lim, HY Yoon, MK Shim, S Lee, YJ Ko, MJ Kim, ... Biomaterials 224, 119494, 2019 | 54 | 2019 |
| Nano-sized metabolic precursors for heterogeneous tumor-targeting strategy using bioorthogonal click chemistry in vivo S Lee, S Jung, H Koo, JH Na, HY Yoon, MK Shim, J Park, JH Kim, S Lee, ... Biomaterials 148, 1-15, 2017 | 54 | 2017 |
| Hydrophobically modified polysaccharide-based on polysialic acid nanoparticles as carriers for anticancer drugs B Jung, MK Shim, MJ Park, EH Jang, HY Yoon, K Kim, JH Kim International Journal of Pharmaceutics 520 (1-2), 111-118, 2017 | 52 | 2017 |
| Artificial chemical reporter targeting strategy using bioorthogonal click reaction for improving active-targeting efficiency of tumor HY Yoon, ML Shin, MK Shim, S Lee, JH Na, H Koo, H Lee, JH Kim, ... Molecular pharmaceutics 14 (5), 1558-1570, 2017 | 46 | 2017 |
| Heat shock responsive drug delivery system based on mesoporous silica nanoparticles coated with temperature sensitive gatekeeper IH Cho, MK Shim, B Jung, EH Jang, MJ Park, HC Kang, JH Kim Microporous and Mesoporous Materials 253, 96-101, 2017 | 45 | 2017 |
| Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance J Kim, MK Shim, S Yang, Y Moon, S Song, J Choi, J Kim, K Kim Journal of controlled release 330, 920-932, 2021 | 44 | 2021 |
| Doxorubicin-loaded PLGA nanoparticles for cancer therapy: molecular weight effect of PLGA in doxorubicin release for controlling immunogenic cell death Y Choi, HY Yoon, J Kim, S Yang, J Lee, JW Choi, Y Moon, J Kim, S Lim, ... Pharmaceutics 12 (12), 1165, 2020 | 43 | 2020 |
| Emerging albumin-binding anticancer drugs for tumor-targeted drug delivery: current understandings and clinical translation H Cho, SI Jeon, CH Ahn, MK Shim, K Kim Pharmaceutics 14 (4), 728, 2022 | 38 | 2022 |
